MX374114B - Combinación de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa. - Google Patents

Combinación de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa.

Info

Publication number
MX374114B
MX374114B MX2019001696A MX2019001696A MX374114B MX 374114 B MX374114 B MX 374114B MX 2019001696 A MX2019001696 A MX 2019001696A MX 2019001696 A MX2019001696 A MX 2019001696A MX 374114 B MX374114 B MX 374114B
Authority
MX
Mexico
Prior art keywords
combination
histamine
inverse agonists
receptor inverse
acetylcholinesterase inhibitors
Prior art date
Application number
MX2019001696A
Other languages
English (en)
Other versions
MX2019001696A (es
Inventor
Abdul Rasheed Mohammed
Anil Karbhari Shinde
Gopinadh Bhyrapuneni
Pradeed Jayarajan
Ramakrishna Nirogi
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2019001696A publication Critical patent/MX2019001696A/es
Publication of MX374114B publication Critical patent/MX374114B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a la combinación de agonista inverso del receptor de histamina 3 e inhibidor de acetilcolinesterasa. También, la presente invención proporciona un agonista inverso del receptor de histamina 3 (H3R) o su sal o sales farmacéuticamente aceptables en combinación o como auxiliar de inhibidores de acetilcolinesterasa y su uso en el tratamiento de trastornos cognitivos. La presente invención también proporciona la composición farmacéutica que contiene dicha combinación.
MX2019001696A 2016-08-18 2017-08-14 Combinación de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa. MX374114B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641028166 2016-08-18
PCT/IB2017/054938 WO2018033847A1 (en) 2016-08-18 2017-08-14 Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors

Publications (2)

Publication Number Publication Date
MX2019001696A MX2019001696A (es) 2019-07-04
MX374114B true MX374114B (es) 2025-03-04

Family

ID=59887325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001696A MX374114B (es) 2016-08-18 2017-08-14 Combinación de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa.

Country Status (28)

Country Link
US (1) US10603323B2 (es)
EP (1) EP3500253B1 (es)
JP (1) JP6734470B2 (es)
KR (1) KR102039585B1 (es)
CN (1) CN109640975B (es)
AU (1) AU2017313427B2 (es)
CA (1) CA3033039C (es)
CY (1) CY1123238T1 (es)
DK (1) DK3500253T3 (es)
EA (1) EA032957B1 (es)
ES (1) ES2810983T3 (es)
HR (1) HRP20201262T1 (es)
HU (1) HUE052003T2 (es)
IL (1) IL264406B (es)
LT (1) LT3500253T (es)
MA (1) MA45990B1 (es)
MD (1) MD3500253T2 (es)
ME (1) ME03812B (es)
MX (1) MX374114B (es)
NZ (1) NZ750150A (es)
PL (1) PL3500253T3 (es)
PT (1) PT3500253T (es)
RS (1) RS60669B1 (es)
SG (1) SG11201900681SA (es)
SI (1) SI3500253T1 (es)
SM (1) SMT202000435T1 (es)
WO (1) WO2018033847A1 (es)
ZA (1) ZA201900467B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3806859T1 (sl) * 2018-05-31 2025-05-30 Suven Life Sciences Limited Postopek zdravljenja z inverznim agonistom receptorja histamina-3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011013437A (es) * 2009-06-10 2012-02-21 Sunovion Pharmaceuticals Inc Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos.
US9079888B2 (en) * 2011-02-23 2015-07-14 Suven Life Sciences Limited Compounds as histamine H3 receptor ligands
FR2974729B1 (fr) 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
SG11201601306QA (en) 2013-09-09 2016-03-30 Sanofi Sa An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

Also Published As

Publication number Publication date
AU2017313427A1 (en) 2019-02-28
SMT202000435T1 (it) 2020-09-10
US10603323B2 (en) 2020-03-31
HUE052003T2 (hu) 2021-04-28
KR20190031330A (ko) 2019-03-25
ME03812B (me) 2021-04-20
MA45990A (fr) 2019-06-26
LT3500253T (lt) 2020-08-25
DK3500253T3 (da) 2020-08-17
NZ750150A (en) 2020-08-28
SG11201900681SA (en) 2019-02-27
EP3500253A1 (en) 2019-06-26
IL264406B (en) 2019-07-31
EA201990480A1 (ru) 2019-05-31
JP6734470B2 (ja) 2020-08-05
KR102039585B1 (ko) 2019-11-01
MA45990B1 (fr) 2020-08-31
SI3500253T1 (sl) 2020-10-30
CN109640975B (zh) 2020-10-20
CY1123238T1 (el) 2021-10-29
AU2017313427B2 (en) 2020-01-30
BR112019002645A2 (pt) 2019-05-28
WO2018033847A1 (en) 2018-02-22
MD3500253T2 (ro) 2020-09-30
CA3033039C (en) 2020-06-23
IL264406A (en) 2019-02-28
CA3033039A1 (en) 2018-02-22
EP3500253B1 (en) 2020-06-24
EA032957B1 (ru) 2019-08-30
JP2019524794A (ja) 2019-09-05
ZA201900467B (en) 2020-06-24
US20190160075A1 (en) 2019-05-30
PL3500253T3 (pl) 2020-11-16
MX2019001696A (es) 2019-07-04
PT3500253T (pt) 2020-08-05
CN109640975A (zh) 2019-04-16
RS60669B1 (sr) 2020-09-30
HRP20201262T1 (hr) 2020-12-11
ES2810983T3 (es) 2021-03-10

Similar Documents

Publication Publication Date Title
MX2020013014A (es) N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX384905B (es) Degradadores de proteínas de bromodominio y dominioextraterminal (bet).
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX380901B (es) Compuestos inhibidores de parg.
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MX389825B (es) Compuestos y composiciones para tratar trastornos hematologicos.
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX2019002396A (es) Composiciones oftalmicas.
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX381768B (es) Combinación de antagonistas puros del receptor 5-ht6 con inhibidores de la acetilcolinesterasa.
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
MX378799B (es) Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.
MX384146B (es) Triple combinación de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
MX374114B (es) Combinación de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa.
JOP20190054A1 (ar) مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
MX387920B (es) Peptidos antagonistas de prgc.
EA201792558A1 (ru) Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль
MX377517B (es) Combinacion triple de agonistas inversos del receptor de histamina 3, inhibidores de acetilcolinestearasa y antagonistas del receptor nmda.
CL2016002125A1 (es) Nuevos compuestos derivados de 6,7-dihidro-3 h-oxazolo (3,4-a) pirazina-5,8-diona
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов

Legal Events

Date Code Title Description
FG Grant or registration